学龄儿童接种减毒活流感疫苗的成本效果分析
研究评估英格兰和威尔士2-16岁儿童接种减毒活流感疫苗(LAIV)的成本效果,比较1995-2013年现行策略与七种替代策略。结果显示所有策略在当前NHS阈值£20,000/QALY下均具成本效果,增量分析表明接种小学生(5-11岁)最具成本效率,ICER为£639/QALY(净效益404 M£ [155, 795])。
要点
- 所有策略在当前NHS阈值£20,000/QALY下100%概率具成本效果。
- 增量分析显示接种小学生(5-11岁)最具成本效率,ICER £639/QALY。
- 建议取消2-4岁接种,聚焦小学和中学的学校接种。
核心结论
- 所有替代策略在当前NHS阈值下均具成本效果,接种小学生最具成本效率。
- 优化现行LAIV儿童策略可取消2-4岁接种,聚焦中小学学校接种。
研究设计与样本
- 经济学评估比较1995-2013年流感疫苗接种项目与七种针对低风险个体的替代策略。
- 替代策略按学前(2-4岁)、小学(5-11岁)、中学(12-16岁)划分。
- 在现状场景(高危亚组和65岁以上接种)基础上进行增量评估。
- 使用传播模型评估接种影响,并更新新数据。
主要发现
- 所有策略在所有覆盖率水平下100%概率在当前NHS阈值£20,000/QALY下具成本效果。
- 增量分析显示接种小学生(5-11岁)最具成本效率,ICER为£639/QALY(净效益404 M£ [155, 795])。
- 覆盖率在30%、55%、70%变化时,包含小学生的策略在较低支付意愿水平下具更高成本效果概率。
- 尽管儿童是接种目标,多数QALY增益发生在25-44岁和65岁以上人群。
- 无论何种策略,甲型H3N2流感株造成的成本和QALY损失最大。
关键数值与推荐
- 当前NHS阈值:£20,000/QALY。
- 接种小学生策略ICER:£639/QALY(净效益404 M£ [155, 795])。
- 覆盖率变化:30%、55%、70%。
临床怎么用
- 优先接种小学生(5-11岁)以优化成本效果。
- 考虑取消2-4岁接种,聚焦小学和中学的学校接种。
- 关注甲型H3N2株的防控,因其造成最大成本和QALY损失。
局限性
- 研究基于模型和既往数据,需实际实施验证。
- 未明确报告模型不确定性范围外的其他局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current pediatric vaccination program in England and Wales administers Live-Attenuated Influenza Vaccine (LAIV) to children ages 2-16 years old. Annual administration of LAIV to this age group is costly and poses substantial logistical issues. This study aims to evaluate the cost-effectiveness of prioritizing vaccination to age groups within the 2-16 year old age range to mitigate the operational and resource challenges of the current strategy. We performed economic evaluations comparing the influenza vaccination program from 1995-2013 to seven alternative strategies targeted at low risk individuals along the school age divisions Preschool (2-4 years old), Primary school (5-11 years old), and Secondary school (12-16 years old). These extensions are evaluated incrementally on the status quo scenario (vaccinating subgroups at high risk of influenza-related complications and individuals 65+ years old). Impact of vaccination was assessed using a transmission model from a previously published study and updated with new data. At all levels of coverage, all strategies had a 100% probability of being cost-effective at the current National Health Service threshold, £20,000/QALY gained. The incremental analysis demonstrated vaccinating Primary School children was the most cost-efficient strategy compared incrementally against others with an Incremental Cost-Effectiveness Ratio of £639 spent per QALY gained (Net Benefit: 404 M£ [155, 795]). When coverage was varied between 30%, 55%, and 70% strategies which included Primary school children had a higher probability of being cost-effective at lower willingness-to-pay levels. Although children were the vaccine target the majority of QALY gains occurred in the 25-44 years old and 65+ age groups. Influenza strain A/H3N2 incurred the greatest costs and QALYs lost regardless of which strategy was used. Improvement could be made to the current LAIV pediatric vaccination strategy by eliminating vaccination of 2-4 year olds and focusing on school-based delivery to Primary and Secondary school children in tandem.
引用
- Wenzel NS, Atkins KE, van Leeuwen E, et al. Cost-effectiveness of live-attenuated influenza vaccination among school-age children. Vaccine. 2020. PMID: 33280855. doi:10.1016/j.vaccine.2020.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。